Antidementia Drugs Withstand Challenge in U.K. Cost-effectiveness restrictions on drugs under Medicare's Part D may be only a matter of time.

Health officials in the United Kingdom have backed off a draft recommendation that would have cut off Alzheimer's disease patients from three antidementia drugs, but they are still recommending limiting the drugs' use to only those patients with moderately severe dementia.